8-K: Zimmer Biomet Announces Solid First Quarter 2025 Results and Updates Full-Year Guidance

Zimmer Biomet reports a 1.1% increase in first quarter net sales, driven by growth in U.S. Hips and the acquisition of Paragon 28, and updates its full-year 2025 revenue and earnings per share guidance.

Summary

• Zimmer Biomet reported first quarter net sales of $1.909 billion, a 1.1% increase compared to the prior year, or 2.3% on a constant currency basis.
• Net earnings for the first quarter were $182.0 million, or $361.1 million on an adjusted basis.
• Diluted earnings per share were $0.91, and adjusted diluted earnings per share were $1.81.
• The company has updated its full-year 2025 reported revenue guidance to 5.7% 8.2%, which includes the Paragon 28 acquisition and currency expectations.
• Full-year 2025 adjusted earnings per share guidance is updated to $7.90 $8.10, including Paragon 28, currency, and the impact from current tariff proposals.
• The company completed the acquisition of Paragon 28, Inc., strengthening its position in the foot and ankle orthopedic segment.
• The FDA granted 510(k) clearance for Persona Revision SoluTion Femur, expected to be commercially available in the U.S. in Q3 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to solid Q1 results, the Paragon 28 acquisition, and updated guidance. However, some concerns exist regarding cost reduction initiatives and certain product category declines.

Positives

• Solid first quarter results with increased net sales and adjusted earnings per share.
• Successful acquisition of Paragon 28, expanding the company's presence in the high-growth foot and ankle segment.
• FDA clearance for Persona Revision SoluTion Femur, providing an alternative for patients with metal sensitivities.
• Updated full-year revenue guidance reflects positive impact of Paragon 28 acquisition.
• The company is named one of the World's Most Ethical Companies by Ethisphere.

Negatives

• Technology & Data, Bone Cement and Surgical sales decreased by 4.7% on a reported basis.
• Adjusted EPS guidance was lowered from $8.15-$8.35 to $7.90-$8.10.
• Restructuring and other cost reduction initiatives of $36 million.

Risks

• The company faces risks related to competition, pricing pressures, and dependence on new product development.
• There are risks associated with integrating the operations of acquired companies, including Paragon 28.
• The company is subject to challenges related to compliance with governmental laws and regulations, including FDA regulations.
• Changes in general domestic and international economic conditions, including currency exchange rate fluctuations, could impact results.
• The company faces risks related to potential breaches or failures of information technology systems, including cyberattacks.

Future Outlook

The company expects full-year 2025 reported revenue to increase by 5.7% to 8.2% and adjusted diluted EPS to be in the range of $7.90 to $8.10.

Management Comments

• We are proud of our teams continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda, said Ivan Tornos, Zimmer Biomets President and Chief Executive Officer.
• Were excited about the momentum in U.S. Hips, fueled by our revamped portfolio inclusive of the Z1 Triple-Taper Femoral Hip System, HAMMR Automated Hip Surgical Impactor System, as well as navigation capabilities, and believe the early enthusiasm from surgeons for our new Oxford Cementless Partial Knee positions us well to accelerate growth in the second half of the year.
• The recently completed acquisition of Paragon 28 is another bold step toward our innovation and diversification ambitions, expanding our S.E.T. business with leading technologies and a dedicated commercial channel in the high-growth foot and ankle segment.

Industry Context

The acquisition of Paragon 28 reflects a broader trend in the medical device industry towards specialization and expansion into high-growth segments like foot and ankle orthopedics. Zimmer Biomet's focus on innovation and digital technologies aligns with the industry's move towards integrated solutions and personalized medicine.

Comparison to Industry Standards

• Competitors like Stryker and Johnson & Johnson also report constant currency revenue growth, but specific comparisons require detailed analysis of their respective Q1 2025 results.
• The adjusted gross margin of 71.5% is competitive within the orthopedic device industry, but benchmarking against peers requires further analysis of their respective margins.
• The company's investment in R&D, representing 5.6% of net sales, is within the typical range for medical technology companies focused on innovation.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased revenue and earnings per share.
• Employees may be affected by restructuring and cost reduction initiatives.
• Customers will have access to a broader portfolio of products and services, including those from Paragon 28.
• The acquisition of Paragon 28 may impact suppliers and distributors of both companies.

Next Steps

• Commercially launch Persona Revision SoluTion Femur in the U.S. in Q3 2025.
• Integrate Paragon 28 into Zimmer Biomet's S.E.T. business.
• Continue to advance innovation agenda and expand digital and robotic technologies.
• Monitor and manage the impact of currency fluctuations and tariff proposals.

Key Dates

Keywords

Zimmer Biomet, financial results, Paragon 28, revenue guidance, earnings per share, medical devices, orthopedics, acquisition, FDA clearance